New drug targets Hard-to-Treat tumors in early trial

NCT ID NCT04249843

Terminated Disease control Sponsor: MapKure, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times

Summary

This study tested a new drug called BGB-3245 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and can shrink tumors. The trial was stopped early, and results are not yet available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Blacktown Hospital

Blacktown, New South Wales, 2148, Australia
Cedars Sinai Medical Center

Beverly Hills, California, 90212, United States
MD Anderson

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
One Clinical Research

Nedlands, Perth, 6009, Australia
Peter MacCallum Cancer Centre

Melbourne, Victoria, 2010, Australia
The Kinghorn Cancer Centre, St Vincent Hospital Sydney

Sydney, New South Wales, 2010, Australia
University of Virginia Comprehensive Cancer Centre

Charlottesville, Virginia, 22903, United States

Conditions

Explore the condition pages connected to this study.

B-RAF MUTATION-RELATED TUMORS B-RAF MUTATION-RELATED TUMORS SOLID TUMOR